Notice2026-22843
Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 10, 2026
Issuing agencies
Justice DepartmentDrug Enforcement Administration
Abstract
The Drug Enforcement Administration (DEA) proposes to establish the 2027 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 216 (Tuesday, November 10, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 216 (Tuesday, November 10, 2026)]
[Notices]
[Pages 72566-72577]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-22843]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1730P]
Proposed Aggregate Production Quotas for Schedule I and II
Controlled Substances and Assessment of Annual Needs for the List I
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Notice with request for comments.
-----------------------------------------------------------------------
SUMMARY: The Drug Enforcement Administration (DEA) proposes to
[[Page 72567]]
establish the 2027 aggregate production quotas for controlled
substances in schedules I and II of the Controlled Substances Act (CSA)
and the assessment of annual needs for the list I chemicals ephedrine,
pseudoephedrine, and phenylpropanolamine.
DATES: Interested persons may file written comments on this notice in
accordance with 21 CFR 1303.11(c) and 1315.11(d). Electronic comments
must be submitted, and written comments must be postmarked, on or
before December 10, 2026. Commenters should be aware that the
electronic Federal Docket Management System will not accept comments
after 11:59 p.m. Eastern Time on the last day of the comment period.
Based on comments received in response to this notice, the
Administrator may hold a public hearing on one or more issues raised.
In the event the Administrator decides in his sole discretion to hold
such a hearing, the Administrator will publish a notice of any such
hearing in the Federal Register. After consideration of any comments or
objections, or after a hearing, if one is held, the Administrator will
publish in the Federal Register a final order establishing the 2027
aggregate production quotas for schedule I and II controlled
substances, and an assessment of annual needs for the list I chemicals
ephedrine, pseudoephedrine, and phenylpropanolamine.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-1730P'' on all correspondence, including any
attachments. DEA encourages that all comments be submitted
electronically through the Federal eRulemaking Portal, which provides
the ability to type short comments directly into the comment field on
the web page or attach a file for lengthier comments. Please go to
<a href="http://www.regulations.gov">www.regulations.gov</a> and follow the online instructions at that site for
submitting comments. Upon completion of your submission, you will
receive a Comment Tracking Number for your comment.
Please be aware that submitted comments are not instantaneously
available for public view on www.Regulations.gov. If you have received
a Comment Tracking Number, your comment has been successfully
submitted, and there is no need to resubmit the same comment. Paper
comments that duplicate electronic submissions are not necessary and
are discouraged. Should you wish to mail a paper comment in lieu of an
electronic comment, it should be sent via regular or express mail to:
Drug Enforcement Administration, Attention: DEA Federal Register
Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia
22152.
FOR FURTHER INFORMATION CONTACT: Heather E. Achbach, Regulatory
Drafting and Policy Support Section, Diversion Control Division, Drug
Enforcement Administration; Mailing Address: 8701 Morrissette Drive,
Springfield, Virginia 22152, Telephone: (571) 776-3882.
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
Please note that all comments received in response to this docket
are considered part of the public record. They will, unless reasonable
cause is given, be made available by the Drug Enforcement
Administration (DEA) for public inspection online at
<a href="http://www.regulations.gov">www.regulations.gov</a>. Such information includes personal identifying
information (such as your name, address, etc.) voluntarily submitted by
the commenter.
The Freedom of Information Act applies to all comments received. If
you want to submit personal identifying information (such as your name,
address, etc.) as part of your comment, but do not want it to be made
publicly available, you must include the phrase ``PERSONAL IDENTIFYING
INFORMATION'' in the first paragraph of your comment. You must also
place all the personal identifying information you do not want made
publicly available in the first paragraph of your comment and identify
what information you want redacted.
If you want to submit confidential business information as part of
your comment, but do not want it to be made publicly available, you
must include the phrase ``CONFIDENTIAL BUSINESS INFORMATION'' in the
first paragraph of your comment. You must also prominently identify
confidential business information to be redacted within the comment.
Comments containing personal identifying information or
confidential business information identified and located as directed
above will generally be made available in redacted form. If a comment
contains so much confidential business information or personal
identifying information that it cannot be effectively redacted, all or
part of that comment may not be made publicly available. Comments
posted to <a href="http://www.regulations.gov">www.regulations.gov</a> may include any personal identifying
information (such as name, address, and phone number) included in the
text of your electronic submission that is not identified as directed
above as confidential.
An electronic copy of this document is available at
<a href="http://www.regulations.gov">www.regulations.gov</a> for easy reference.
Legal Authority
Section 306 of the Controlled Substances Act (21 U.S.C. 826)
requires the Attorney General to establish production quotas for each
basic class of controlled substances listed in schedules I and II, and
for the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine. The Attorney General has delegated this function
to the Administrator of DEA pursuant to 28 CFR 0.100.
Analysis for Proposed 2027 Aggregate Production Quotas and Assessment
of Annual Needs
The proposed 2027 aggregate production quotas (APQ) and assessment
of annual needs (AAN) represent those quantities of schedule I and II
controlled substances, and the list I chemicals ephedrine,
pseudoephedrine, and phenylpropanolamine, to be manufactured in the
United States in 2027 to provide for the estimated medical, scientific,
research, and industrial needs of the United States, lawful export
requirements, and the establishment and maintenance of reserve stocks.
These quotas include imports of ephedrine, pseudoephedrine, and
phenylpropanolamine, but do not include imports of controlled
substances for use in industrial processes.
Aggregate Production Quotas
In determining the proposed 2027 APQ, the Administrator has taken
into account the criteria of 21 U.S.C. 826(a) and 21 CFR 1303.11,
including the following seven factors:
(1) Total net disposal of the class by all manufacturers during the
current and two preceding years;
(2) Trends in the national rate of net disposal of the class;
(3) Total actual (or estimated) inventories of the class and of all
substances manufactured from the class, and trends in inventory
accumulation;
(4) Projected demand for such class as indicated by procurement
quotas requested pursuant to [21 CFR] 1303.12;
(5) The extent of any diversion of the controlled substance in the
class;
(6) Relevant information obtained from the Department of Health and
Human Services (HHS), including from the Food and Drug Administration
(FDA), the Centers for Disease Control
[[Page 72568]]
and Prevention (CDC), and the Centers for Medicare and Medicaid
Services (CMS), and relevant information obtained from the states; and
(7) Other factors affecting medical, scientific, research, and
industrial needs in the United States and lawful export requirements,
as the Administrator finds relevant, including changes in the currently
accepted medical use in treatment with the class or the substances
manufactured from it, the economic and physical availability of raw
materials for use in manufacturing and for inventory purposes, yield
and stability problems, potential disruptions to production (including
possible labor strikes), and recent unforeseen emergencies such as
floods and fires.
21 CFR 1303.11(b).
DEA formally solicited data from FDA and CDC in March of 2026 and
from the states in April 2026, pursuant to 21 CFR part 1303. DEA did
not solicit input from CMS for reasons discussed in previous
notices.\1\ DEA requested information on trends in the legitimate use
of select schedule I and II controlled substances from FDA and rates of
overdose deaths for covered controlled substances from CDC. DEA's
request for information from the states was made directly to the
Prescription Drug Monitoring Program (PDMP) Administrators in each
state as well as through the National Association of State Controlled
Substances Authorities (NASCSA).
---------------------------------------------------------------------------
\1\ Proposed Adjustments to the Aggregate Production Quotas for
Schedule I and II Controlled Substances and Assessment of Annual
Needs for List I Chemicals Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2020, 85 FR 54414 (Sept. 1, 2020) and
Proposed Aggregate Production Quotas for Schedule I and II
Controlled Substances and Assessment of Annual Needs for List I
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for
2021, 85 FR 54407 (Sept. 1, 2020).
---------------------------------------------------------------------------
Assessment of Annual Needs
In similar fashion, in determining the proposed 2027 AAN for the
list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine,
the Administrator has taken into account the criteria of 21 U.S.C.
826(a) and 21 CFR 1315.11, including the following five factors:
(1) Total net disposal of the chemical by all manufacturers and
importers during the current and two preceding years;
(2) Trends in the national rate of net disposal of each chemical;
(3) Total actual (or estimated) inventories of the chemical and of
all substances manufactured from the chemical, and trends in inventory
accumulation;
(4) Projected demand for each chemical as indicated by procurement
and import quotas requested pursuant to [21 CFR] 1315.32; and
(5) Other factors affecting medical, scientific, research, and
industrial needs in the United States, lawful export requirements, and
the establishment and maintenance of reserve stocks, as the
Administrator finds relevant, including changes in the currently
accepted medical use in treatment with the chemicals or the substances
manufactured from them, the economic and physical availability of raw
materials for use in manufacturing and for inventory purposes, yield
and stability problems, potential disruptions to production (including
possible labor strikes), and recent unforeseen emergencies such as
floods and fires.
21 CFR 1315.11(b).
In determining the proposed 2027 AAN, DEA used the calculation
methodology previously described in the 2010 and 2011 assessments of
annual needs (74 FR 60294 (Nov. 20, 2009) and 75 FR 79407 (Dec. 20,
2010), respectively).
Projected Trends for Certain Schedule II Controlled Substances
In accordance with 21 CFR part 1303, 21 U.S.C. 826, and 42 U.S.C.
242, HHS continues to provide DEA with estimates of the quantities of
select schedule I and II controlled substances and three list I
chemicals that will be required to meet the legitimate medical needs of
the United States for a given calendar year. The responsibility to
provide these estimates of legitimate domestic medical needs resides
with FDA. FDA provides DEA with predicted estimates of domestic medical
usage for selected controlled substances based on information available
to them at a specific point in time in order to meet statutory
requirements. In July 2026, FDA provided DEA with the predicted
estimates of domestic medical usage for selected controlled substances
for 2027, which DEA considered in developing the proposed 2027 APQ.
FDA predicts that levels of medical usage for schedule II opioids
in the United States in calendar year 2027 will decline on average 9.68
percent from calendar year 2026 levels. These declines are expected to
occur across a variety of schedule II opioids including fentanyl,
hydrocodone, hydromorphone, oxycodone, and oxymorphone. DEA considered
the potential for diversion of schedule II opioids, as required by 21
CFR 1303.11(b)(5), in developing the proposed 2027 APQ. Accordingly,
the APQs for fentanyl, hydrocodone (for sale), hydromorphone, oxycodone
(for sale), and oxymorphone (for sale) are being proposed as reductions
from their 2026 proposed revised APQ values.
FDA also provided a predicted 3.93 percent increase on average of
domestic medical use of schedule II stimulants in calendar year 2027,
including d-amphetamine (for sale), d,l-amphetamine, lisdexamfetamine,
and methylphenidate, which are prescribed to treat patients with
attention deficit hyperactivity disorder (ADHD), from calendar year
2026 levels. FDA also raised concerns over drug shortages potentially
related to the growth in telemedicine, supply chain issues,
manufacturing and quality issues, and business decisions of
manufacturers, which DEA considered in developing the proposed 2027
APQ. DEA recently proposed to increase the 2026 APQs for both
lisdexamfetamine and methylphenidate (for sale) and is proposing the
same increased values for 2027 in part to address these concerns.
DEA is proposing the 2027 APQs for the schedule II stimulants d,l-
amphetamine and d-amphetamine (for sale) at higher levels than their
2026 proposed revised APQ values to address the growth in prescribing,
export requirements, the global market, and to ensure sufficient
inventory for domestic manufacturers of FDA-approved drug products.
Medications containing one or both of these controlled substances are
commonly prescribed to treat patients with ADHD. Over the past few
years, dosage form manufacturers have been intermittently reporting
shortages of specific ADHD medications containing amphetamine to FDA.
The stated reasons for these specific shortages include increases in
product demand, supply chain issues, manufacturing and quality issues,
lack of active ingredients, and business decisions of manufacturers.
FDA estimated a 3.90 percent increase in domestic medical usage
individually for d-amphetamine (for sale) and d,l- amphetamine. DEA
reviewed the most recently available domestic usage data from IQVIA and
export data from DEA's internal database and Multi International Data
Analysis System (MIDAS). The projection from this data estimated use
for d-amphetamine (for sale) and d,l-amphetamine each increased by 6.98
percent. DEA also considered the manufacturers' reported inventories
for amphetamine-based products and their drug shortage concerns when
determining the proposed APQs for these substances. DEA believes the
inventories, when combined with the proposed 2027 APQs, will be
sufficient to support the estimated increases in
[[Page 72569]]
domestic medical use and export requirements of amphetamine products.
DEA is proposing the pentobarbital APQ at a higher level than the
2026 established APQ to support Executive Order 14336: Ensuring
American Pharmaceutical Supply Chain Resilience by Filling the
Strategic Active Pharmaceutical Ingredients Reserve. The 2027 proposed
pentobarbital increase is greater than the 2026 proposed revised APQ to
allow for a reserve stockpile of the API for manufacturing established
essential medications containing pentobarbital based on the request
from Administration for Strategic Preparedness and Response (ASPR).
DEA Projected Trends for Certain Schedule I Controlled Substances
On August 12, 2026, DEA published in the Federal Register a
temporary scheduling order to place O-desmethyltramadol in schedule I
of the CSA until August 12, 2028, or until a permanent schedule action
of this substance is complete, whichever occurs first.\2\ Therefore,
DEA is proposing an APQ for this basic class for the first time. DEA is
also proposing the 2027 APQs for acetyl fentanyl and heroin at lower
levels than their 2026 proposed revised APQ based on the decline in the
amount of quota requested to support medical, scientific, research, and
industrial needs. These decreases in the APQs will not affect the
ability of these manufacturers to meet the estimated medical,
scientific, research, and industrial needs of the U.S., lawful export
requirements, and the establishment and maintenance of reserve stocks.
---------------------------------------------------------------------------
\2\ 91 FR 52013 (August 12, 2026).
---------------------------------------------------------------------------
DEA is proposing higher APQs than the 2026 proposed revised APQs
for the following schedule I controlled substances: 3,4-
Methylenedioxymethamphetamine (MDMA) and ibogaine to support
manufacturing activities related to the increased level of research and
clinical trials being conducted with these substances for potential
treatment of conditions including post-traumatic stress disorder (PTSD)
and depression. This increase in research and clinical trials aligns
with two Presidential Executive Orders (E.O.). First, E.O. 14379:
Addressing Addiction through the Great American Recovery Initiative,\3\
which prioritizes addiction treatment and recovery. Second, E.O. 14401:
Accelerating Medical Treatments for Serious Mental Illness,\4\ which
requires a pathway to be established for eligible patients to access
psychedelic drugs, including ibogaine compounds, under the Right to Try
Act (21 U.S.C. 360bbb-0a). Additionally, DEA is proposing a lower APQ
than the 2026 proposed revised APQ for fentanyl-related substances
based on the diminished needs of manufacturers who produce reference
standards or support research.
---------------------------------------------------------------------------
\3\ Addressing Addiction Through the Great American Recovery
Initiative, Executive Order 14379 of January 29, 2026.
\4\ Accelerating Medical Treatments for Serious Mental Illness,
Executive Order 14401 of April 18, 2026.
---------------------------------------------------------------------------
Information Received for Consideration of the Remaining Factors
For the factors listed in 21 CFR 1303.11(b)(3) and (4), DEA
registered manufacturers of controlled substances in schedules I and II
provide information such as inventory, distribution, manufacturing,
sales forecasts and quota requests to DEA database systems. See, 21 CFR
1303.12, 1303.22, and part 1304.
The regulation at 21 CFR 1303.11(b)(5) requires DEA to consider the
extent of diversion of controlled substances.\5\ Diversion is defined
as all distribution, dispensing, or other use of controlled substances
for other than legitimate medical purposes. In considering the extent
of diversion, DEA analyzed reports of diversion of controlled
substances from 2025 submitted to its Theft Loss Report database. This
database is comprised of DEA registrant reports documenting diversion
from the legitimate distribution chain, including employee thefts,
break-ins, armed robberies, and material lost in transit. The data was
categorized by basic drug class, and the amount of Active
Pharmaceutical Ingredient (API) in the dosage form was delineated with
an appropriate metric for use in proposing aggregate production quota
values (i.e., weight).
---------------------------------------------------------------------------
\5\ The estimates of diversion for five ``covered controlled
substances'' as required by 21 U.S.C. 826(i) are discussed later in
the document.
---------------------------------------------------------------------------
Estimates of Diversion of Covered Controlled Substances
In establishing any quota . . . , or any procurement quota
established by [DEA] by regulation, for fentanyl, oxycodone,
hydrocodone, oxymorphone, or hydromorphone (in this subsection referred
to as a ``covered controlled substance''), [DEA] shall estimate the
amount of diversion of the covered controlled substance that occurs in
the United States.
21 U.S.C. 826(i)(1)(A).
In estimating diversion under that provision, DEA:
(i) shall consider information . . . , in consultation with the
Secretary of Health and Human Services, [it] determines reliable on
rates of overdose deaths and abuse and overall public health impact
related to the covered controlled substance in the United States; and
(ii) may take into consideration whatever other sources of
information [it] determines reliable.
21 U.S.C. 826(i)(1)(B).
The statute further mandates that DEA ``make appropriate quota
reductions, as determined by [DEA], from the quota [it] would have
otherwise established had such diversion not been considered.'' \6\
---------------------------------------------------------------------------
\6\ 21 U.S.C. 826(i)(1)(C).
---------------------------------------------------------------------------
In estimating the amount of diversion of each covered controlled
substance that occurs in the United States, DEA considered information
from state PDMP Administrators and from legitimate distribution chain
participants.
Consideration of Information From Certain State PDMPs and From National
Sales Data
Pursuant to 21 CFR 1303.11(b)(6), DEA requested state PDMP data for
the purpose of establishing its APQ. DEA believes state PDMPs to be an
essential, reliable source of information for use in effectively
estimating diversion of the five covered controlled substances. In
April 2026, DEA sent a letter to NASCSA requesting its assistance in
obtaining aggregated PDMP data for the five covered controlled
substances from each state covering the years 2022-2025. The letter
indicated that DEA was specifically interested in an analysis of
prescription data from each state's PDMP that would assist DEA in
estimating diversion and setting appropriate quotas in compliance with
21 U.S.C. 826(i). In its request, DEA provided specific questions,
discussed in detail below, based on common indicia of potential
diversion known as ``red flags'' by physicians, pharmacists,
manufacturers, distributors, and federal and state regulatory and law
enforcement agencies.\7\ DEA investigators and administrative
prosecutors also rely on Agency case law in which these red flags of
diversion have been upheld as indicia of potential diversion.\8\
Certain state regulations
[[Page 72570]]
now include red flag circumstances as potential indicators of
illegitimate prescriptions, and thus of potential abuse and diversion
of controlled substances.\9\ See, e.g., The Pharmacy Place Order, 86 FR
21008, 21012 (Apr. 21, 2021) (citing 22 Tex. Admin. Code 291.29(c)(4),
specifying the geographical distance between the practitioner and the
patient or between the pharmacy and the patient as a red flag).
---------------------------------------------------------------------------
\7\ National Association of Boards of Pharmacy (NABP) coalition
consensus document ``Stakeholders' Challenges and Red Flag Warning
Signs Related to Prescribing and Dispensing Controlled Substances''
(2015). www.nabp.pharmacy/resources/reports.
\8\ The Medicine Shoppe, 79 FR 59504, 59507, 59512-13 (Oct. 2,
2014); Holiday CVS, L.L.C., d/b/a CVS Pharmacy Nos. 219 and 5195, 77
FR 62316 (Oct. 12, 2012).
\9\ The mere indicia of red flags alone is not proof of
violation of 21 U.S.C. 824 or any other provision of the CSA. This
rule discusses only their use by DEA as an analytical tool to
estimate diversion.
---------------------------------------------------------------------------
DEA requested responses from state PDMP Administrators by June 15,
2026. NASCSA disseminated DEA's request to its PDMP Administrators and
provided them with a report tool to ensure that responses to DEA's
questions were extracted consistently across all responsive states.
Thirty-six states and two territories provided DEA with summarized PDMP
data as of July 2026, utilizing the standardized report developed by
NASCSA.\10\ See, Table 1a below.
---------------------------------------------------------------------------
\10\ NASCSA formatted DEA's request into an analytics model
developed by one of its associates, Appriss Inc.
Table 1a--States/Territories That Responded to DEA's Data Request
------------------------------------------------------------------------
State/territory
-------------------------------------------------------------------------
1. Alabama
2. Alaska
3. Arkansas
4. Connecticut
5. Delaware
6. Florida
7. Idaho
8. Illinois
9. Indiana
10. Iowa
11. Kansas
12. Louisiana
13. Maine
14. Maryland
15. Massachusetts
16. Michigan
17. Minnesota
18. Mississippi
19. Missouri
20. Montana
21. Nevada
22. New Jersey
23. New Mexico
24. New York
25. North Carolina
26. North Dakota
27. Ohio
28. Oklahoma
29. Oregon
30. Pennsylvania
31. South Carolina
32. South Dakota
33. Texas
34. Utah
35. Vermont
36. Virginia
37. Puerto Rico
38. Northern Mariana Islands
------------------------------------------------------------------------
Pharmacies are required by state law to enter controlled substance
dispensing data into the state's PDMP database, including the
prescriber's name, registered address and DEA number; prescription
information (such as drug name); dispensing date; dosage dispensed;
pharmacy registered address; and patient name and address. DEA
considers PDMP data to be an accurate representation of dispensing
activities in states. DEA received data for the following red-flag
metrics:
<bullet> The total number of patients who saw three or more
prescribers in a 90-day period and were dispensed an opioid following
each visit. For this metric, DEA requested and was provided the number
of prescriptions for the five covered controlled substances dispensed
to these patients, as a percentage of the total prescriptions dispensed
for that particular covered controlled substance, as well as the
corresponding quantity of the covered controlled substance dispensed.
This metric (patients being prescribed covered controlled substances
from three or more prescribers in a 90-day period) is used to identify
potential doctor shopping, a common technique to obtain a high number
of controlled substances, which may lead to abuse or diversion of
controlled substances. DEA has long considered doctor shopping to be an
indicator of potential diversion.\11\
---------------------------------------------------------------------------
\11\ Frank's Corner Pharmacy, 60 FR 17574 (Apr. 6, 1995);
Holiday CVS, L.L.C., d/b/a CVS Pharmacy Nos. 219 and 5195, 77 FR
62316 (Oct. 12, 2012).
---------------------------------------------------------------------------
<bullet> The number of patients that were dispensed prescriptions
for each of the five covered controlled substances that exceeded 240
morphine milligram equivalents (MME) daily. States provided the raw
number of such prescriptions dispensed, the number of prescriptions as
a percentage of the total covered controlled substance prescriptions
dispensed, and the corresponding quantity of the covered controlled
substance dispensed. DEA believes that accounting for quantities in
excess of 240 MME daily allows for consideration of oncology patients
with legitimate medical needs for covered controlled substance
prescriptions with high MME. Higher dosages place individuals at higher
risk of overdose and death. Prescriptions involving dosages exceeding
240 MME daily may indicate diversion, such as illegal distribution of
controlled substances or prescribing outside the usual course of
professional practice.
<bullet> The number of patients that paid cash for covered
controlled substance prescriptions, without submitting for insurance
reimbursement.\12\ States also provided the number of prescriptions
paid entirely with cash as a percentage of the total prescriptions for
the five covered controlled substances dispensed, as well as the
corresponding quantity of the covered controlled substances dispensed.
When investigating potential diversion, cash payments are one element
considered in identifying prescriptions filled for nonmedical purposes.
Unusually high percentages of cash payments made to a prescriber or
pharmacy for controlled substances may indicate diversion.\13\
---------------------------------------------------------------------------
\12\ This total does not include insurance co-payments made with
cash.
\13\ Suntree Pharmacy and Suntree Medical Equipment, LLC, 85 FR
73753 (Nov. 19, 2020) (finding that the pharmacy filled
prescriptions despite the presence of multiple unresolved red flags,
including cash payments); Pharmacy Doctors Enterprises d/b/a Zion
Clinic Pharmacy, 83 FR 10876 (Mar. 13, 2018) (revoking pharmacy's
registration for filling prescriptions that raised the red flag of
customers paying cash for their prescriptions, among other red
flags).
---------------------------------------------------------------------------
DEA received PDMP data from the states in a standardized format
that allowed DEA to aggregate the data. The PDMP data sample represents
a population of approximately 213.76 million people, which is
approximately 62 percent of the U.S. population. DEA believes this
sample is sufficient to derive a reasonable nationwide estimate.
While PDMP data is useful in estimating diversion, it is not
conclusive. Further investigation would be required before concluding
that any of the subject prescriptions were actually diverted. DEA
continues to evaluate its methodologies in estimating diversion in an
effort to set quotas more efficiently. State participation is crucial
to accurate data analysis, and DEA anticipates working closely with
states, as well as other federal and state entities, in future quota
determinations.
To calculate a national diversion estimate for each of the covered
controlled substances from the responses received from state PDMP
Administrators, DEA relied upon the number of individuals who received
a prescription for a covered controlled substance that met any of the
three red-flag metrics for each of calendar years 2022-2025. Using the
population of the states responding to DEA's request, DEA
[[Page 72571]]
then calculated the percentage of the population issued a prescription
with a red flag. Using this estimated percentage for 2022-2025, DEA
analyzed trends in the data to predict the estimated percentage of
patients who would be expected to be included in these red-flag metrics
for 2027.
DEA also reviewed aggregate sales data for each of the covered
controlled substances, which it extracted from IQVIA's National Sales
Perspective.\14\ IQVIA sales data was selected to help quantify
diversion at the national level because it reflects the best national
estimate for all prescriptions written and filled, including the total
quantity available for diversion or misuse. To predict the estimated
national sales for 2027, DEA analyzed trends in IQVIA sales data from
January 2021-April 2026.
---------------------------------------------------------------------------
\14\ DEA has purchased this data from IQVIA for decades and
routinely uses this information to administer several regulatory
functions, including the administration of DEA's quota program.
---------------------------------------------------------------------------
To estimate diversion for each of the covered controlled
substances, DEA multiplied the forecasted percentage of patients likely
to receive a prescription for a covered controlled substance that meet
any of the three red-flag metrics in 2027 by the forecasted sales data
from IQVIA for 2027. The resulting estimate of diversion from data
submitted by state PDMP Administrators is summarized below in Table 1b.
This data contributed to the final diversion estimate set forth in
Table 3.
Table 1b--Diversion Estimates for 2027 Based on State PDMP Data for
Covered Controlled Substances for 2025
------------------------------------------------------------------------
Controlled substance (g)
------------------------------------------------------------------------
Fentanyl................................................... 46
Hydrocodone................................................ 126,636
Hydromorphone.............................................. 595
Oxycodone.................................................. 380,276
Oxymorphone................................................ 0
------------------------------------------------------------------------
Consideration of Registrant Reported Diversion in the Legitimate
Distribution Chain
DEA extracted data from its Theft Loss Report database and
categorized it by each basic drug class. DEA calculated the estimated
amount of diversion by multiplying the quantity of API in each finished
dosage form by the total amount of units reported stolen or lost to
estimate the metric weight in grams of the controlled substance being
diverted. This estimate of diversion from the legitimate supply chain
for each of the covered controlled substances is displayed in Table 2.
This data contributed to the final diversion estimates set forth in
Table 3.
Table 2--Diversion Estimates Based on Supply Chain Diversion Data for
Covered Controlled Substances
------------------------------------------------------------------------
Controlled substance (g)
------------------------------------------------------------------------
Fentanyl................................................... 162
Hydrocodone................................................ 9,213
Hydromorphone.............................................. 582
Oxycodone.................................................. 27,441
Oxymorphone................................................ 97
------------------------------------------------------------------------
In accordance with 21 U.S.C. 826(i), DEA's estimate of diversion
for the five controlled substances was calculated by combining the
values in Tables 1b and 2.
Table 3--Total Estimates of Diversion for Covered Controlled Substances
To Be Considered in the 2027 APQs
------------------------------------------------------------------------
Controlled substance (g)
------------------------------------------------------------------------
Fentanyl................................................... 208
Hydrocodone................................................ 135,849
Hydromorphone.............................................. 1,177
Oxycodone.................................................. 407,717
Oxymorphone................................................ 97
------------------------------------------------------------------------
Continuing Efforts to Anticipate and Prevent Drug Shortages
DEA remains committed to monitoring drug shortages, limiting their
impact, and resolving them as quickly as possible. DEA continues to
seek additional information that will assist in accurately forecasting
domestic medical usage and export requirements of schedule I or II
substances. As documented in the 2026 established APQ Federal Register
notice DEA began utilizing IQVIA's foreign (non-U.S.) sales tracking
data module in February 2024, MIDAS, which provides valuable insight
into the growing export markets for schedule II stimulants. In March
2025, DEA sent a letter requesting DEA-registered manufacturers and
distributors to voluntarily switch their DEA ARCOS database reporting
from a quarterly to monthly basis. As of July 14, 2026, 47% of all
ARCOS reporting DEA-registered manufacturers, distributors and reverse
distributors report to ARCOS monthly. DEA remains committed to ensuring
that all patients with legitimate medical need can access appropriately
prescribed medications.
Quota Requirements for Controlled Substances in Schedule III of the
Controlled Substances Act
On April 28, 2026, the Acting Attorney General issued Schedules of
Controlled Substances: Rescheduling of Food and Drug Administration
Approved Products Containing Marijuana From Schedule I to Schedule III;
Corresponding Change to Permit Requirements as a final rule which
became effective on April 28, 2026.\15\ This final rule places in
schedule III drug products containing marijuana that have been approved
by the FDA and drug products subject to a state medical marijuana
license. The final rule assigned separate drug codes for schedule III
marijuana in an FDA-approved product or subject to a state medical
marijuana license, schedule III marijuana extract in an FDA-approved
product or subject to a state medical marijuana license, and schedule
III naturally-derived delta-9-tetrahydrocannabinols in an FDA-approved
product or subject to a state medical marijuana license (drug codes
7362, 7353, 7386).
---------------------------------------------------------------------------
\15\ 91 FR 22714 (April 28, 2026).
---------------------------------------------------------------------------
The final rule outlines several control measures required to
satisfy the United States obligations under the Single Convention on
Narcotic Drugs, 1961, as well as the CSA. Two related control measures
of the Single Convention require: (1) manufacturers and distributors of
drugs listed in Schedule I of the Convention, including marijuana, to
be licensed (Articles 29 & 30); and (2) licensed manufacturers of drugs
listed in Schedule I of the Convention obtain quotas specifying the
amounts of such drugs they may manufacture to prevent excessive
production and accumulation beyond that necessary to satisfy legitimate
needs. (Articles 21 & 29). DEA is currently in the process of
registering the manufacturers and distributors who will be handling the
substances that have been moved to schedule III under the CSA as
outlined in the final rule. Concurrently, DEA is assessing data sources
and methodologies to determine the most reliable and relevant datasets
for the estimation of the United States' legitimate need and production
requirements for these 3 substances. Therefore, the APQ table below
continues to reflect the APQs for the schedule I marijuana, marijuana
extract, and delta-9-tetrahydrocananbinol (drug codes 7360, 7350, 7370)
only. A separate notice will be published in the Federal Register once
the proposed APQs for the schedule III substances
[[Page 72572]]
(drug codes 7362, 7353, 7386) are determined.
The Administrator, therefore, proposes to establish the 2027 APQ
for certain schedule I and II controlled substances and AAN for the
list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine,
expressed in grams of anhydrous acid or base, as follows:
------------------------------------------------------------------------
Established 2027
Basic class quotas (g)
------------------------------------------------------------------------
Temporary Schedule I
------------------------------------------------------------------------
2-Fluorodeschloroketamine............................ 30
5-Methyl Etodesnitazene.............................. 30
Bromazolam........................................... 30
Ethyleneoxynitazene.................................. 30
Methylenedioxynitazene............................... 30
N,N-Dimethylamino Etonitazene........................ 30
N-Desethyl Etonitazene............................... 30
N-Desethyl Protonitazene............................. 30
N-Pyrrolidino Isotonitazene.......................... 30
O-Desmethyltramadol.................................. 30
------------------------------------------------------------------------
Schedule I
------------------------------------------------------------------------
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine............... 20
1-(1-Phenylcyclohexyl)pyrrolidine.................... 30
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine....... 10
1-(4-Methoxyphenyl)-N-methylpropan-2-amine (Para- 30
methoxymethamphetamine).............................
1-(5-Fluoropentyl)-3-(1-naphthoyl) indole (AM2201)... 30
1-Benzylpiperazine................................... 25
1-Methyl-4-phenyl-4-propionoxypiperidine............. 10
1-[1-(2-Thienyl)cyclohexyl]piperidine................ 15
2'-Fluoro 2-fluorofentanyl........................... 30
2,5-Dimethoxy-4-Ethylamphetamine (DOET).............. 25
2,5-Dimethoxy-4-(n)-Propylthiophenethylamine......... 25
2,5-Dimethoxyamphetamine............................. 25
2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P) 30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)..... 30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D).... 30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N).... 30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)............. 100
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2- 30
methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe;
25B; Cimbi-36)......................................
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2- 25
methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe;
25C; Cimbi-82)......................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C).... 30
2-(4-Ethoxybenzyl)-5-Nitro-1-(2-(Piperidin-1- 30
yl)Ethyl)-1H-Benzimidazole (N-Piperidinyl
Etonitazene)........................................
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2- 30
methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe;
25I; Cimbi-5).......................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)...... 30
2-(Ethylamino)-2-(3-Methoxyphenyl)Cyclohexan-1-One 30
(Methoxetamine).....................................
2-Methyl AP-237...................................... 30
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T- 30
2)..................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine 30
(2C-T-4)............................................
3,4,5-Trimethoxyamphetamine.......................... 30
3,4-Methylenedioxyamphetamine (MDA).................. 12,000
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)......... 40
3,4-Methylenedioxy-N-methylcathinone (methylone)..... 42,500
3,4-Methylenedioxymethamphetamine (MDMA)............. 33,296
3,4-Methylenedioxypyrovalerone (MDPV)................ 35
3-FMC; 3-Fluoro-N-methylcathinone.................... 25
3-Methoxyphencyclidine (1-(1-(3- 30
Methoxyphenyl)cyclohexyl)piperidine)................
3-Methylfentanyl..................................... 30
3-Methylthiofentanyl................................. 30
3-Methylmethcathinone................................ 30
4'-Methyl acetyl fentanyl............................ 30
4'-Methyl-alpha-pyrrolidinohexiophenone (MPHP)....... 25
4,4'-Dimethylaminorex................................ 30
4-Bromo-2,5-dimethoxyamphetamine (DOB)............... 30
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)........... 5,100
4-Chloro-alpha-pyrrolidinovalerophenone (4-chloro- 25
alpha-PVP)..........................................
4-Chloromethcathinone................................ 30
4-CN-Cumyl-Butinaca.................................. 25
4-Fluoroamphetamine.................................. 30
4-Fluoroisobutyryl fentanyl.......................... 30
4-FMC; Flephedrone................................... 25
4-MEC; 4-Methyl-N-ethylcathinone..................... 25
4-Methoxyamphetamine................................. 150
[[Page 72573]]
4-Methyl-2,5-dimethoxyamphetamine (DOM).............. 25
4-Methyl-alpha-ethylaminopentiophenone (4-MEAP)...... 25
4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP).... 25
4-Methyl-N-methylcathinone (mephedrone).............. 45
4-Methylaminorex..................................... 25
4F-MDMB-BUTICA....................................... 30
5-Fluoro-PB-22; 5F-PB-22............................. 25
5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3- 25
yl](2,2,3,3-tetramethylcyclopropyl)methanone........
5-Methoxy-3,4-methylenedioxyamphetamine.............. 25
5-Methoxy-N,N-diisopropyltryptamine.................. 25
5-Methoxy-N,N-dimethyltryptamine..................... 30,000
5F-AB-PINACA ; (1-Amino-3-methyl-1-oxobutan-2-yl)-1- 25
(5-fluoropentyl)-1H-indazole-3-carboxamide..........
5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)- 25
1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)...
5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3- 25
carboxamido)-3-methylbutanoate).....................
5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5- 25
fluoropentyl)-1H-indazole-3-carboxamide)............
5F-CUMYL-P7AICA; 1-(5-Fluoropentyl)-N-(2-phenylpropan- 25
2-yl)-1H-pyrrolo[2,3-b]pyridine-3carboximide........
5F-CUMYL-PINACA...................................... 25
5F-EDMB-PICA......................................... 30
5F-EDMB-PINACA....................................... 25
5F-MDMB-PICA......................................... 25
A-PIHP; 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1- 30
one (alpha-PiHP)....................................
AB-CHMINACA.......................................... 30
AB-FUBINACA.......................................... 50
AB-PINACA............................................ 30
Acetorphine.......................................... 25
Acetyl Fentanyl...................................... 30
Acetyl-alpha-methylfentanyl.......................... 30
Acetyldihydrocodeine................................. 30
Acetylmethadol....................................... 25
Acryl Fentanyl....................................... 25
ADB-4en-PINACA....................................... 30
ADB-BUTINACA......................................... 30
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2- 30
yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)...
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- 50
1-pentyl-1H-indazole-3-carboxamide).................
AH-7921.............................................. 30
All other tetrahydrocannabinol....................... 1,166,130
Allylprodine......................................... 25
alpha-Ethyltryptamine................................ 25
alpha-Methylfentanyl................................. 30
alpha-Methylthiofentanyl............................. 30
alpha-Methyltryptamine (AMT)......................... 25
alpha-Pyrrolidinobutiophenone ([alpha]-PBP).......... 25
alpha-pyrrolidinoheptaphenone (PV8).................. 25
alpha-pyrrolidinohexabophenone (alpha-PHP)........... 25
alpha-Pyrrolidinopentiophenone ([alpha]-PVP)......... 25
Alphacetylmethadol................................... 25
Alphameprodine....................................... 25
Alphamethadol........................................ 25
Amineptine........................................... 30
Aminorex............................................. 25
Anileridine.......................................... 20
APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3- 25
carboxamide)........................................
Benzethidine......................................... 25
Benzylmorphine....................................... 30
beta-Hydroxy-3-methylfentanyl........................ 30
beta-Hydroxyfentanyl................................. 30
beta-Hydroxythiofentanyl............................. 30
beta-Methyl fentanyl................................. 30
beta-Methylacetyl fentanyl........................... 30
beta'-Phenyl fentanyl................................ 30
Betacetylmethadol.................................... 25
Betameprodine........................................ 25
Betamethadol......................................... 25
Betaprodine.......................................... 25
Brorphine............................................ 30
Bufotenine........................................... 15
Butonitazene......................................... 30
Butylone............................................. 25
Butyryl fentanyl..................................... 30
Cathinone............................................ 40
Cannabimimetic Agents................................ 620
[[Page 72574]]
Clonazolam........................................... 30
Clonitazene.......................................... 25
Codeine methylbromide................................ 30
Codeine-N-oxide...................................... 192
Crotonyl Fentanyl.................................... 25
CUMYL-PEGACLONE...................................... 30
Cyclopentyl Fentanyl................................. 30
Cyclopropyl Fentanyl................................. 20
Cyprenorphine........................................ 25
delta-9-Tetrahydrocannabinol......................... 1,523,040
Desomorphine......................................... 25
Dextromoramide....................................... 25
Diapromide........................................... 20
Diclazepam........................................... 30
Diethylthiambutene................................... 20
Diethyltryptamine.................................... 25
Difenoxin............................................ 9,300
Dihydromorphine...................................... 639,954
Dimenoxadol.......................................... 25
Dimepheptanol........................................ 25
Dimethylthiambutene.................................. 20
Dimethyltryptamine................................... 25,000
Dioxyaphetyl butyrate................................ 25
Dipentylone.......................................... 30
Dipipanone........................................... 25
Drotebanol........................................... 25
Ethylmethylthiambutene............................... 25
Ethylone............................................. 25
Ethylphenidate....................................... 30
Etizolam............................................. 30
Etodesnitazene....................................... 30
Etonitazene.......................................... 25
Etorphine............................................ 30
Etoxeridine.......................................... 25
Eutylone............................................. 30
Fenethylline......................................... 30
Fentanyl carbamate................................... 30
Fentanyl related substances.......................... 300
Flualprazolam........................................ 30
Flubromazolam........................................ 30
Flunitazene.......................................... 30
FUB-144.............................................. 25
FUB-AKB48............................................ 25
FUB-AMB, MMB-Fubinaca, AMB-Fubinaca.................. 25
Furanyl fentanyl..................................... 30
Furethidine.......................................... 25
gamma-Hydroxybutyric acid............................ 49,675,266
Heroin............................................... 100
Hexahydrocannabinol.................................. 30
Hydromorphinol....................................... 40
Hydroxypethidine..................................... 25
Ibogaine............................................. 12,002
Isobutyryl Fentanyl.................................. 25
Isotonitazine........................................ 25
JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole)... 35
Ketobemidone......................................... 30
Levomoramide......................................... 25
Levophenyacylmorphan................................. 25
Lysergic acid diethylamide (LSD)..................... 1,200
MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1- 30
oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
carboxamide)........................................
Marijuana............................................ 6,675,000
Marijuana extract.................................... 1,000,000
MDMB-4EN-PINACA...................................... 30
MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1- 30
(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-
dimethylbutanoate)..................................
MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H- 30
indazole-3-carboxamido)-3,3-dimethylbutanoate)......
Mecloqualone......................................... 30
Mescaline............................................ 1,200
Mesocarb............................................. 30
meta-Fluorofuranyl fentanyl.......................... 30
Methaqualone......................................... 60
[[Page 72575]]
Methcathinone........................................ 25
Methiopropamine...................................... 30
Methoxyacetyl fentanyl............................... 30
Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3- 30
carboxamido)-3,3-dimethylbutanoate (4F-MDMB-BINACA).
Methyldesorphine..................................... 5
Methyldihydromorphine................................ 25
Metodesnitazene...................................... 30
Metonitazene......................................... 30
MMB-CHMICA; (AMB-CHIMCA); Methyl-2-(1- 25
(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-
methylbutanoate.....................................
MMB-FUBICA........................................... 30
Morpheridine......................................... 25
Morphine methylbromide............................... 5
Morphine methylsulfonate............................. 5
Morphine-N-oxide..................................... 150
MT-45................................................ 30
Myrophine............................................ 25
N,N-Dimethylamphetamine.............................. 25
N-Ethyl-1-phenylcyclohexylamine...................... 25
N-Desethyl Isotonitazene (N-Ethyl-2-(2-(4- 30
isopropoxybenzyl)-5-nitro-1H- benzimidazol-1-
yl)ethan-1-amine)...................................
N-Ethyl-3-piperidyl benzilate........................ 10
N-Ethylamphetamine................................... 24
N-Ethylhexedrone..................................... 25
N-Ethylpentylone, ephylone........................... 30
N-Hydroxy-3,4-methylenedioxyamphetamine.............. 24
N-Methyl-3-piperidyl benzilate....................... 30
N-Pyrrolidino Etonitazene............................ 30
N-pyrrolidino metonitazene........................... 30
N-pyrrolidino protonitazene.......................... 30
Naphyrone............................................ 25
Nicocodeine.......................................... 25
Nicomorphine......................................... 25
NM2201: Naphthalen-1-yl 1-(5-fluorpentyl)-1H-indole-3- 25
carboxylate.........................................
Noracymethadol....................................... 25
Norlevorphanol....................................... 2,550
Normethadone......................................... 25
Normorphine.......................................... 40
Norpipanone.......................................... 25
Ocfentanil........................................... 25
ortho-Chlorofentanyl................................. 30
ortho-Fluoroacryl fentanyl........................... 30
ortho-Fluorobutyryl fentanyl......................... 30
ortho-Fluorofentanyl,2-Fluorofentanyl................ 30
ortho-Fluoroisobutyryl fentanyl...................... 30
ortho-Methyl acetylfentanyl.......................... 30
ortho -Methylcyclopropylfentanyll.................... 30
ortho-Methyl methoxyacetyl fentanyl.................. 30
para-Chlorofentanyl.................................. 30
para-Chloroisobutyrl fentanyl........................ 30
para-Flourobutyryl fentanyl.......................... 25
para-Fluorofentanyl.................................. 25
para-Fluoro furanyl fentanyl......................... 30
para-Fluoro valeryl fentanyl......................... 30
para-Methoxybutyrl fentanyl.......................... 30
para-Methylfentanyl.................................. 30
Parahexyl............................................ 5
PB-22; QUPIC......................................... 20
Pentedrone........................................... 25
Pentylone............................................ 25
Phenadoxone.......................................... 25
Phenampromide........................................ 25
Phenomorphan......................................... 25
Phenoperidine........................................ 25
Phenyl fentanyl...................................... 30
Pholcodine........................................... 5
Piritramide.......................................... 25
Proheptazine......................................... 25
Properidine.......................................... 25
Propiram............................................. 25
Protonitazene........................................ 30
Psilocybin........................................... 60,000
Psilocyn............................................. 93,600
[[Page 72576]]
Racemoramide......................................... 25
Tetrahydrofuranyl fentanyl........................... 15
Tetrahydrothiofuranyl fentanyl....................... 30
Thebacon............................................. 25
Thiafentanil......................................... 25
Thiofentanyl......................................... 25
Thiofuranyl fentanyl................................. 30
THJ-2201 ( [1-(5-fluoropentyl)-1H-indazol-3- 30
yl](naphthalen-1-yl)methanone)......................
Tilidine............................................. 25
Trimeperidine........................................ 25
U-47700.............................................. 30
UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3- 25
tetramethylcyclopropyl)methanone....................
Valeryl fentanyl..................................... 25
Zipeprol............................................. 30
------------------------------------------------------------------------
Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine.............................. 15
1-Piperidinocyclohexanecarbonitrile.................. 25
4-Anilino-N-phenethyl-4-piperidine (ANPP)............ 937,874
Alfentanil........................................... 5,000
Alphaprodine......................................... 25
Amobarbital.......................................... 20,100
Bezitramide.......................................... 25
Carfentanil.......................................... 20
Cocaine.............................................. 60,492
Codeine (for conversion)............................. 942,452
Codeine (for sale)................................... 19,262,516
d-Amphetamine (for conversion)....................... 41,392,071
d-Amphetamine (for sale)............................. 38,486,179
d-Methamphetamine (for conversion)................... 485,020
d-Methamphetamine (for sale)......................... 47,000
d,l-Amphetamine...................................... 32,902,638
d,l-Methamphetamine.................................. 150
Dexmethylphenidate (for conversion).................. 5,374,683
Dexmethylphenidate (for sale)........................ 6,200,000
Dextropropoxyphene................................... 35
Dihydrocodeine....................................... 115,227
Dihydroetorphine..................................... 25
Diphenoxylate (for conversion)....................... 14,100
Diphenoxylate (for sale)............................. 770,800
Ecgonine............................................. 60,492
Ethylmorphine........................................ 30
Etorphine hydrochloride.............................. 32
Fentanyl............................................. 731,028
Glutethimide......................................... 25
Hydrocodone (for conversion)......................... 1,250
Hydrocodone (for sale)............................... 26,842,228
Hydromorphone........................................ 2,355,621
Isomethadone......................................... 30
l-Amphetamine........................................ 30
l-Methamphetamine.................................... 587,229
Levo-alphacetylmethadol (LAAM)....................... 25
Levomethorphan....................................... 30
Levorphanol.......................................... 20,000
Lisdexamfetamine..................................... 62,832,521
Meperidine........................................... 681,184
Meperidine Intermediate-A............................ 30
Meperidine Intermediate-B............................ 30
Meperidine Intermediate-C............................ 30
Metazocine........................................... 15
Methadone (for sale)................................. 25,619,700
Methadone Intermediate............................... 27,673,600
Methylphenidate (for conversion)..................... 19,975,468
Methylphenidate (for sale)........................... 69,502,651
Metopon.............................................. 25
Moramide-intermediate................................ 25
Morphine (for conversion)............................ 2,393,200
Morphine (for sale).................................. 23,000,000
Nabilone............................................. 62,000
Norfentanyl.......................................... 25
[[Page 72577]]
Noroxymorphone (for conversion)...................... 24,756,979
Noroxymorphone (for sale)............................ 2,500
Oliceridine.......................................... 25,100
Opium (powder)....................................... 250,000
Opium (tincture)..................................... 530,837
Oripavine............................................ 45,721.950
Oxycodone (for conversion)........................... 437,827
Oxycodone (for sale)................................. 49,829,934
Oxymorphone (for conversion)......................... 31,773,105
Oxymorphone (for sale)............................... 464,270
Pentobarbital........................................ 55,216,002
Phenazocine.......................................... 25
Phencyclidine........................................ 35
Phenmetrazine........................................ 25
Phenylacetone........................................ 100
Piminodine........................................... 25
Racemethorphan....................................... 5
Racemorphan.......................................... 5
Remifentanil......................................... 6,152
Secobarbital......................................... 172,100
Sufentanil........................................... 4,000
Tapentadol........................................... 10,390,226
Thebaine............................................. 57,137,944
------------------------------------------------------------------------
List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion)........................... 41,100
Ephedrine (for sale)................................. 3,933,336
Phenylpropanolamine (for conversion)................. 15,500,000
Phenylpropanolamine (for sale)....................... 7,990,000
Pseudoephedrine (for conversion)..................... 1,000
Pseudoephedrine (for sale)........................... 186,617,466
------------------------------------------------------------------------
The Administrator further proposes that the APQ for all other
schedule I and II controlled substances included in 21 CFR 1308.11 and
1308.12 remain at zero.
These proposed 2027 quotas reflect the quantities that DEA believes
are necessary to meet the estimated medical, scientific, research, and
industrial needs of the United States, lawful export requirements; and
the establishment and maintenance of reserve stocks.
In accordance with 21 CFR 1303.13 and 1315.13, upon consideration
of the relevant factors, the Administrator may adjust the 2027 APQ and
AAN as needed.
Conclusion
After consideration of any comments or objections, or after a
hearing, if one is held, the Administrator will issue and publish in
the Federal Register a final order establishing the 2027 APQ for
controlled substances in schedules I and II and establishing an AAN for
the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine, as directed by 21 CFR 1303.11(c) and 1315.11(f).
Signing Authority
This document of the Drug Enforcement Administration was signed on
November 3, 2026, by DEA Administrator Terrance C. Cole. That document
with the original signature and date is maintained by DEA. For
administrative purposes only, and in compliance with requirements of
the Office of the Federal Register, the undersigned DEA Federal
Register Liaison Officer has been authorized to sign and submit the
document in electronic format for publication, as an official document
of DEA. This administrative process in no way alters the legal effect
of this document upon publication in the Federal Register.
Heather Achbach,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2026-22843 Filed 11-9-26; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on November 10, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.